Unknown

Dataset Information

0

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.


ABSTRACT: The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response remains moderate. Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response. Little is known about how sequential dual targeting of tumor tissue tension and vasculature before chemotherapy can affect tumor response. We used intravital imaging to assess how transient manipulation of the tumor tissue, or "priming," using the pharmaceutical Rho kinase inhibitor Fasudil affects response to chemotherapy. Intravital Förster resonance energy transfer imaging of a cyclin-dependent kinase 1 biosensor to monitor the efficacy of cytotoxic drugs revealed that priming improves pancreatic cancer response to gemcitabine/Abraxane at both primary and secondary sites. Transient priming also sensitized cells to shear stress and impaired colonization efficiency and fibrotic niche remodeling within the liver, three important features of cancer spread. Last, we demonstrate a graded response to priming in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer.

SUBMITTER: Vennin C 

PROVIDER: S-EPMC5777504 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

Vennin Claire C   Chin Venessa T VT   Warren Sean C SC   Lucas Morghan C MC   Herrmann David D   Magenau Astrid A   Melenec Pauline P   Walters Stacey N SN   Del Monte-Nieto Gonzalo G   Conway James R W JR   Nobis Max M   Allam Amr H AH   McCloy Rachael A RA   Currey Nicola N   Pinese Mark M   Boulghourjian Alice A   Zaratzian Anaiis A   Adam Arne A S AA   Heu Celine C   Nagrial Adnan M AM   Chou Angela A   Steinmann Angela A   Drury Alison A   Froio Danielle D   Giry-Laterriere Marc M   Harris Nathanial L E NL   Phan Tri T   Jain Rohit R   Weninger Wolfgang W   McGhee Ewan J EJ   Whan Renee R   Johns Amber L AL   Samra Jaswinder S JS   Chantrill Lorraine L   Gill Anthony J AJ   Kohonen-Corish Maija M   Harvey Richard P RP   Harvey Richard P RP   Biankin Andrew V AV   Evans T R Jeffry TR   Anderson Kurt I KI   Grey Shane T ST   Ormandy Christopher J CJ   Gallego-Ortega David D   Wang Yingxiao Y   Samuel Michael S MS   Sansom Owen J OJ   Burgess Andrew A   Cox Thomas R TR   Morton Jennifer P JP   Pajic Marina M   Timpson Paul P  

Science translational medicine 20170401 384


The emerging standard of care for patients with inoperable pancreatic cancer is a combination of cytotoxic drugs gemcitabine and Abraxane, but patient response remains moderate. Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response. Little is known about how sequential dual targeting of tumor tissue tension and vasculature before chemotherapy can affect tumor response. W  ...[more]

Similar Datasets

| S-EPMC6959285 | biostudies-literature
| S-EPMC6376180 | biostudies-literature
2023-04-23 | GSE224688 | GEO
| S-EPMC7301481 | biostudies-literature
| S-EPMC5601149 | biostudies-literature
| S-EPMC5841864 | biostudies-other
| S-EPMC7086362 | biostudies-literature
| S-EPMC5354718 | biostudies-literature
| S-EPMC6383192 | biostudies-literature
| S-EPMC4592394 | biostudies-literature